EnVivo Pharmaceuticals, Inc. is dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS). The company’s focus is on building an integrated company and it is working to convert its broad pipeline into a range of CNS therapies that leverage novel mechanisms of action by altering the progression of diseases and providing improvement in cognitive and overall function. EnVivo’s lead product is an alpha-7 nicotinic acetylcholine receptor agonist that has successfully completed Phase 2b clinical trials in both schizophrenia and Alzheimer’s disease. EnVivo’s other development programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi), a Gamma Secretase Modulator program and a potent and selective PDE10 inhibitor program.

Location choice

Anticipating further growth, EnVivo wanted to establish a European office. Buck Consultants International was asked to compare a number of European locations on location factors such as the availability of suitable personnel, size of biopharmaceutical cluster and capabilities, real estate options and expat climate. EnVivo decided for Leiden, the Netherlands. Within this university town, only 20 kilometers from Amsterdam Schiphol Airport, a large Bio Science Park exists, with already 85 life sciences companies. “We are proud of our new location in Leiden”, said Kees Been, President and CEO of EnVivo Pharmaceuticals, Inc. “We look forward to establishing our European presence as we progress our pipeline of novel centrals nervous system therapies”. Henri Lenferink, mayor of the city of Leiden comments: “We believe this is a great decision for EnVivo, the park and our city. I am convinced that a bright future for EnVivo lies ahead”. The Leiden Bio Science Park, the West-Holland Foreign Investment Agency and the Netherlands Foreign Investment Agency together paved the way for EnVivo in Leiden.

Learn more about this topic or want to discuss this topic with an expert?

Receive news from BCI